ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 72 filers reported holding ORIC PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $169,944 | -31.8% | 21,900 | -49.9% | 0.00% | -100.0% |
| Q1 2023 | $249,090 | -71.2% | 43,700 | -70.3% | 0.00% | -66.7% |
| Q4 2022 | $865,241 | +70.3% | 146,900 | -7.4% | 0.00% | +50.0% |
| Q3 2022 | $508,000 | -40.4% | 158,600 | -16.6% | 0.00% | 0.0% |
| Q2 2022 | $852,000 | +45.4% | 190,200 | +73.2% | 0.00% | +100.0% |
| Q1 2022 | $586,000 | +4.3% | 109,800 | +187.4% | 0.00% | 0.0% |
| Q4 2021 | $562,000 | -29.7% | 38,200 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $799,000 | +24.8% | 38,200 | +5.5% | 0.00% | +100.0% |
| Q2 2021 | $640,000 | +110.5% | 36,205 | +192.0% | 0.00% | 0.0% |
| Q1 2021 | $304,000 | -27.6% | 12,400 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $420,000 | +20.7% | 12,400 | -10.8% | 0.00% | 0.0% |
| Q3 2020 | $348,000 | -25.8% | 13,900 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $469,000 | – | 13,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 602,272 | $4,673,631 | 14.75% |
| Nextech Invest Ltd. | 4,285,714 | $33,257,141 | 11.30% |
| Column Group LLC | 3,568,181 | $27,689,085 | 10.75% |
| Prosight Management, LP | 5,522,936 | $42,857,984 | 6.42% |
| Invus Financial Advisors, LLC | 1,007,575 | $7,818,782 | 4.18% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,450,822 | $11,258,379 | 3.48% |
| VR Adviser, LLC | 2,142,856 | $16,628,563 | 2.66% |
| Euclidean Capital LLC | 747,550 | $5,800,988 | 1.49% |
| Frazier Life Sciences Management, L.P. | 2,142,855 | $16,628,555 | 0.99% |
| Monaco Asset Management SAM | 378,222 | $2,935,003 | 0.82% |